Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Inhibikase Therapeutics (IKT) Shares Outstanding (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Shares Outstanding for 6 consecutive years, with $74.8 million as the latest value for Q3 2025.

  • Quarterly Shares Outstanding rose 902.24% to $74.8 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $74.8 million through Sep 2025, up 902.24% year-over-year, with the annual reading at $69.4 million for FY2024, 1021.23% up from the prior year.
  • Shares Outstanding for Q3 2025 was $74.8 million at Inhibikase Therapeutics, roughly flat from $74.5 million in the prior quarter.
  • The five-year high for Shares Outstanding was $74.8 million in Q3 2025, with the low at $12000.0 in Q3 2023.
  • Average Shares Outstanding over 5 years is $21.7 million, with a median of $6.5 million recorded in 2024.
  • The sharpest move saw Shares Outstanding plummeted 99.72% in 2023, then soared 62100.58% in 2024.
  • Over 5 years, Shares Outstanding stood at $4.2 million in 2021, then grew by 0.28% to $4.2 million in 2022, then soared by 46.45% to $6.2 million in 2023, then soared by 1021.23% to $69.4 million in 2024, then increased by 7.85% to $74.8 million in 2025.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $74.8 million, $74.5 million, and $74.3 million for Q3 2025, Q2 2025, and Q1 2025 respectively.